STOCKS TELEGRAPH

Author: Maria Masood

  • Galapagos NV (GLPG) Stock High in Premarket. Here’s the Reason.

    Galapagos NV (GLPG) is a leading biotherapeutics company engaged in development and commercialization of therapies using small molecules. The pipeline project of the company includes filgotinib used in treating rheumatoid arthritis, ulcerative colitis and other diseases. GLPG1690 is tested against idiopathic pulmonary fibrosis and NOVESA for systemic sclerosis.

    The price of GLPG stock during the regular trading on January 26, 2022 was $53.32 with a slight decrease of 0.04%. At last check in the premarket on January 27, 2022, the stock sharply inclined by 12.08%.

    GLPG: Events and Happenings

    On 26 January 2022, GLPG reported about the approval of its Subscription Right Plan 2022 by the company’s supervisory board. The plan created up to 1,000,000 subscription rights which have eight years exercise term.

    On January 18, 2022, GLPG reported about the grant of approval for the marketing of filgotinib by the Medicines and Healthcare products Regulatory Agency. On January 6 2022, GLPG reported that the Company’s Executives presented at 40th Annual J.P. Morgan Healthcare Conference held on January 10-13, 2022.

    On December 3, 2021, GLPG reported an incline in its share capital due to its subscription right exercises. The company issued 22,600 ordinary shares for a total capital rise of €0.57 million. On November 22, 2021, GLPG reported about the closure of enrolment during its Phase 2 clinical studies of MANGROVE.

    On November 15, 2021, GLPG reported about the grant of approval for the marketing of filgotinib by the European Commission.

    GLPG: Key Financials

    On November 4, 2021, GLPG reported its financial results for the quarter ended September 30, 2021. Some of the key updates are as follows.

    Revenue

    Collaboration revenue in Q3 2021 was €58.5 million compared to €127.5 million in the same period of 2020.

    Net Loss per Share

    Basic and diluted net loss per share in Q3 2021 was €64.6 million or €0.99 compared to €81.9 million or €1.25 in the same period in 2020.

    Conclusion

    GLPG stock down performed from the past six months period by 11% due to sluggish economic development in pandemic conditions. The current premarket increase in stock price is the result of creation of new subscription right plan by the company. The investors and experts are eager to see the company blooming.

  • Ondas Holdings Inc. (ONDS) Stock Rising in the Early Trading. Here’s the Reason.

    Ondas Holdings Inc. (ONDS) Stock Rising in the Early Trading. Here’s the Reason.

    Ondas Holdings Inc. (ONDS) is an important drone solution and wireless data providing company. The company operates through contemporary software-based wireless broadband technology for catering to different industrial markets. The company overcomes the limitations of bandwidth of private licensed wireless platforms.

    The price of ONDS stock during the early trading session on January 26, 2022 was last checked to be $4.99 with a significant increase of 10.04%.

    ONDS: Events and Happenings

    On January 26, 2022, ONDS reported about the receipt of an acquisition order from Chevron for automated Scout Systems by its subsidiary. The number of customers of the subsidiary grew to two after the placement of this order. ONDS reported On December 28, 2021, about the development of a research program for rail communications at Penn State RTE platform by its subsidiary.

    ONDS reported On December 21, 2021, about the receipt of an order of radio systems for the Rail Lab in North America by its subsidiary. On November 30, 2021, ONDS reported its subsidiary’s Mercury Radio had been approved to use in 450 MHz frequency band.

    ONDS: Key Financials

    On November 15, 2021, ONDS reported its financial results for the third quarter ended September 30, 2021. Some of the key aspects are as follows.

    Revenue

    Revenue declined by 54% over the yearly period. The total revenue in Q3 2021 was $0.3 million compared to $0.6 million for the same period in 2020.

    Assets

    Total current assets in the third quarter 2021 were $50.6 million.

    Net Loss per Share

    Basic and diluted net loss per share in Q3 2021 was $4.9 million or $0.13 versus $3.3 million or $0.17 for the same period in 2020.

    Conclusion

    ONDS stock is on the declining verge from the last half year as a deceleration of 36% was observed during the period. The recent early trades flourished stock is the outcome of order placement by a leading company. The analysts believe that this step will prove fruitful in the company’s development in coming days.

  • Vaccinex, Inc. (VCNX) Stock on The Rise Today, Here’s The Reason

    Vaccinex, Inc. (VCNX) is a pioneer company utilizing modern approach against oncological diseases. The lead product candidate of the company is pepinemab which has the potential to cure different cancers as well as Alzheimer’s disease and osteosarcoma. VX5 is another potential candidate for therapeutic potential against autoimmune diseases.

    The price of VCNX stock during the regular trading on January 25, 2022 was $1.02 with a slight increase of 0.99%. At last check in the current market, the stock was further up by 22.5%.

    VCNX: Events and Happenings

    On January 26, 2022, VCNX reported optimistic response results for the KEYNOTE-B84 safety trials of pepinemab. The company collaborated with KEYTRUDA therapy of Merck for this purpose. The study was conducted on patients with head and neck squamous cell cancer.

    VCNX: CEO Comments

    Speaking at the occasion, VCNX CEO Maurice Zauderer said that by merging pepinemab with KEYTRUDA will decrease the chances of the process of chemotherapy. He further added that the company is looking forward to share further optimistic outcomes at a conference.

    On November 10, 2021, VCNX reported about the management’s poster presentation for pepinemab effect on patients. The poster was presented at the 36th Annual Meeting of Society for Immunology of Cancer on November 12-14, 2021. On November 09, 2021, VCNX reported about presentation of Executives at the Clinical Trials on Alzheimer’s Disease Meeting on November 11, 2021.

    VCNX: Key Financials

    On November 08, 2021, VCNX reported its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.

    Revenue and Assets

    Revenue in Q3 2021 was $0.05 million versus $0.6 million in the same period of 2020. The total current assets in third quarter 2021 were recorded to be $14.8 million.

    Net Loss per Share

    Basic and diluted net loss per share in Q3 2021 was $5.2 million or $0.17 against $8.7 million or $0.44 in same period prior year.

    Conclusion

    VCNX didn’t performed well during the last six months period as the company’s stock fell 56% during that time. The current premarket stock boom is the consequence of complete responses in the patients regarding KEYNOTE-B84 studies. The financial specialists are optimistic that the company is outperforming to attract potential investment.

  • Here’s the Reason why Immix Biopharma, Inc. (IMMX) Stock is Volatile in Premarket

    Here’s the Reason why Immix Biopharma, Inc. (IMMX) Stock is Volatile in Premarket

    Immix Biopharma, Inc. (IMMX) is a global and important biotherapeutics firm developing tissue specific therapeutics. The company’s clinical pipeline targets cancers and immumo-dysregulatory disorders. One of the lead candidates is IMX-110 in Phase 1/2 trials for soft tissue sarcoma and rhabdomyosarcoma treatment. TME Normalization technology cuts the tumor and its metabolic growth pathways.

    The price of IMMX stock during the regular trading on January 25, 2022 was $4.12 with a dip of 2.6%. The stock first showed over 10% gains in the premarket on January 26, 2022, but at last check, it was slightly down by 0.48%.

    IMMX: Events and Happenings

    On January 25, 2022, IMMX reported the outcomes of IMX-110 + anti-PD-1 combination. It increased medium survival range to 63-day in a mouse model. The mice developed its peculiar pancreatic tumor and had an undamaged immuno-regulatory platform. On January 25, 2022, the company filed S-8 form with the SEC regarding its securities registration.

    IMMX reported hopeful clinical studies safety results on January 19, 2022. The company demonstrated full completion of IMX-110 therapeutic sequences. The company also reported no disruptions related to the drug.

    On January 12, 2022, IMMX reported the 50% response-rate results of IMX-110 in a mouse model for soft tissue sarcoma studies. The response was evaluated by RECIST 1.1 standard with development evaluated after one therapeutic cycle.

    IMMX reported on January 06, 2022, about its event regarding Investors Day, which will be held on February 1, 2022.  On January 03, 2022, IMMX reported about the grant of Rare Pediatric Disease status by FDA to IMX-110.

    On December 20, 2021, IMMX reported the closure of its preliminary public offering of 4,200,000 shares. The public offering price of the shares of its common stock was $5.00. The net proceeds resulted from the offering were $21,000,000. Additionally, IMMX also granted the acquisition of extra 630,000 shares at the public price.

    Conclusion

    IMMX stock performed well during the last six months period as it swelled 12% during the period. The current decrease in stock can be attributed to its recent SEC filing regarding securities to be offered to employees in employee benefit plans. The analysts are optimistic that the company will reap the benefits of its important strategic collaborations.

  • Here’s why Weidai Ltd. (WEI) Stock Rocketing Higher in Today’s Premarket

    Weidai Ltd. (WEI) is providing financing solutions for automobile-backed industry in China. The company is engaged in the transformation of secondhand autos into investable possessions. The company also utilizes sophisticated and efficient risk management technology for its customers.

    The price of WEI stock during the regular trading on January 25, 2022 was $2.22 with a steep rise of 345%. At last check in the premarket on January 26, 2022, the stock further inclined by 26% to $2.82 thanks to an ADS ratio change that’s equivalent to a five-for-one reverse stock split.

    WEI: Events and Happenings

    On January 25, 2022, WEI reported about changing the ratio of the company’s American Depositary Shares. The impact of modification will be seen at the start of trading on January 26. The modification succeeds the previous strategy of 3:1 share change ratio.

    On November 18, 2021, WEI reported about holding of annual general meeting of the company’s stockholders on December 15, 2021. The meeting served as an open discussion forum for stockholders. On September 24, 2021, WEI reported about receipt of notification from NYSE as the company’s ADS was below the standard compliance price.

    WEI: Key Financials

    On August 27, 2021, WEI reported its financial results for the first fiscal six months ended June 30, 2021. Some of the key updates are as follows.

    Revenue

    Net revenue in H1 2021 was recorded to be RMB535.9 million.

    Net Loss per Share

    Basic and diluted net loss during the first half of 2021 was RMB397.1 million or RMB5.61 per share.

    Conclusion

    WEI stock is performing great in the market as it gained 116% from the past six months despite the challenges faced due to deteriorating economic conditions. The current premarket stock surge is the result of company’s updated ratio change of shares. The analysts are predicting this bloom in the stock will help the company to gain additional benefits from different investors.

  • Canadian National Railway Company (CNI) Stock Plunging in Aftermarket. Here’s the Reason.

    Canadian National Railway Company (CNI) is a leading global transportation front-runner and it enables the trade in different regions. The company transports approximately transports 300 million tons of goods safely throughout US. Vessels and docks facilities are also provided by the company along with transport management platforms.

    The price of CNI stock during the regular trading on January 25, 2022, was $122.46 with an incline of 0.72%. At last check in the aftermarket the stock went down by 5.28%.

    CNI: Events and Happenings

    On January 25, 2022, CNI reported about its entry into Resolution Contract with TCI and CIFF Capital. The company also notified changes in the Board by its commitment regarding the appointment of Directors to its Board.

    On January 25, 2022, CNI reported about appointing Tracy Robinson as the company’s new CEO with effect from February 28, 2022.  On January 25, 2022, CNI reported about the approval of reacquisition of its shares by BoDs via new bid. The company also increased its outstanding common shares dividend of 2022 to 19%.

    CNI: Key Financials

    On January 25, 2022, CNI reported its financial results for the fourth quarter ended December 31, 2021. Some of the key updates are as follows.

    Revenue

    Total revenue in Q4 2021 was recorded to be Canadian $3,753 million compared to C$3656 million in same quarter prior year.

    Net Income per Share

    Diluted net income per share in Q4 2021 was C$1199 million or C$1.69 versus C$1021 million or C$1.43 in the same period prior year.

    On January 13, 2022, CNI reported about its intention to file an open application notification for reviewing the Kansas City Southern and Canadian Pacific combination on February 28, 2022.

    On December 21, 2021, CNI reported about the approval of auction of non-core assets and rail lines in Michigan and Wisconsin by the US STB. The company was also involved in selling its Soo subdivision.

    On December 14, 2021, CNI co-reported with Google Cloud about their entry into a seven years strategic collaboration for the transformation of its supply chain. The company is aiming to digitalize and modernize its technology infrastructure.

    Conclusion

    CNI stock is outperforming from the last six months period as it surged by 16% due to the thorough policies of the company. The current aftermarket stock dip is likely the result of company’s resolution contract with TCI. The analysts believe that the company should focus on investor relation building to improve its stocks stats.

  • Doma Holdings Inc. (DOMA) Stock Gaining Momentum in Aftermarket. Here’s What’s Happening.

    Doma Holdings Inc. (DOMA) is a real estate transactions company. The company utilizes AI-based learning techniques and its exclusive technology to reshape the residential real estate industry. It also offers solutions for modest and effective closings to the proprietors.

    The price of Doma Holdings stock during the regular trading on January 5, 2022, was $3.54 with a decrease of 1.12%. At last check in the aftermarket, the stock was significantly up by 3.67%.

    DOMA: Events and Happenings

    On January 5, 2022, DOMA reported that its title solutions are steering the development of AdvantageFirst. The company uses its tech-driven, Intelligence platform-powered technologies for this purpose.

    Doma Holdings: CEO Comments

    Speaking at the occasion, the company’s CEO Max Simkoff said that he is impressed by AdvantageFirst’s efficiency gains by the implementation of its technology. He further added that AdvantageFirst is dedicated to providing a prompt, online closing experience to the consumers.

    DOMA reported on December 20, 2021, about the growth of its Intelligence portfolio to different US states. The company reported on December 1, 2021, that its Chief Data Science Officer was awarded by HousingWire as the Tech Trendsetter 2021.

    On November 30, 2021, Doma Holdings reported that the company’s Executives presented at the KBW Innovation in Finance Virtual Conference on December 7. On November 17, 2021, DOMA reported that the company’s Executives presented at the JMP Securities Financial Services and Real Estate Conference on November 18, 2021.

    Doma Holdings: Key Financials

    On November 10, 2021The company announced its financial results for the three months ended September 30, 2021. Some of the key updates are as follows.

    Revenue

    Total revenues in Q3, 2021 were $163 million compared to $121 million in the same period of 2020.

    Net Loss per Share

    Basic and diluted net loss per share in Q3, 2021 was $34.2 million or $0.14 versus $3.6 million or $0.06 in the same period the prior year.

    Conclusion

    Doma Holdings stock down-performed 63% from the past six months period as there is global economic recession due to the recent pandemic. The current aftermarket increase is the outcome of uncertain factors influencing the company’s stock price. The analysts are optimistic that the company’s pace of development is satisfactory.

  • Turquoise Hill Resources Ltd. (TRQ) Stock Shining in Early Trading. Here’s the Reason.

    Turquoise Hill Resources Ltd. (TRQ) Stock Shining in Early Trading. Here’s the Reason.

    Turquoise Hill Resources Ltd. (TRQ) is a leading global mining firm focused on the exploration of copper, silver and gold deposits. It is fundamentally engaged in the development of Mongolian copper-gold mine known as the Oyu Tolgoi.

    The price of TRQ stock during the early trading on January 25, 2022 was $17.3 with a sharp surge of 14.57% after a breakthrough deal with the Mongolian government.

    TRQ: Events and Happenings

    On January 24, 2022, TRQ reported about the renovation of its collaboration with the the Oyu Tolgoi LLC and Mongolian Government. The company will now commence the undercut or blasting that will begin the OT’s underground mine making. Subsequently, the Company is also planning to start caving programs in the days to come. The company is hopeful that the mine will attain sustainable manufacture for Panel 0 in H1 2023.

    On January 17, 2022, TRQ reported its Q4 2021 production and financial and operational guidance for 2022. Some of the key points are as follows

    • Copper production in full year 2021 stood at 163 thousand tonnes
    • Gold production in full year 2021 stood at 468 thousand ounces
    • Milling throughput for full year 2021 stood at 39.1 million tonnes

    On December 13, 2021, TRQ reported taking notice of the media coverage about talks between the company, Rio Tinto and the Mongolian government.

    TRQ: Key Financials

    On November 2, 2021, TRQ reported its financial results for the quarter ended September 30, 2021. Some of the key updates are as follows.

    Revenue

    Revenue in Q3 2021 was recorded to be $622.8 million compared to $264.4 million in the same period in 2020.

    Net Income per Share

    Basic and diluted net income per share in Q3 2021 was $22.9 million or $0.17 compared to $161.7 million or $0.64 in the same period of 2020.

    Conclusion

    TRQ stock is 09% up for the past six months period due to the sound policies of the company’s management. The recent premarket growth of the stock is outcome of commencement of underground mines and renewed partnership with Mongolian government. The analysts are hopeful with the output of the company’s stock and attributed it to the investors interest in company.

  • Spire Global, Inc. (SPIR) Stock Gaining Momentum in Premarket, Here’s What Happened.

    Spire Global, Inc. (SPIR) Stock Gaining Momentum in Premarket, Here’s What Happened.

    Spire Global, Inc. (SPIR) is an international key space-based data and analytics provider offering utilizing exclusive datasets. It is a multi-purpose satellite constellation to cause difficult to purchase, valued data and augments it with analytical solutions.

    The price of SPIR stock during the regular trading on January 24, 2022 was $2.3 with a surge of 3.61%. At last check in the premarket on January 25, 2022, the stock was further up by 0.87%.

    SPIR: Events and Happenings

    On January 21, 2022, SPIR reported about its entry into a collaboration with Dragonfly Aerospace thus supporting the ONI of Australian Government with a second satellite. The follow-up portfolio will be used by the company to design, build and launch its LEMUR satellite platform. After its launch, the company has the capacity of computing and processing of AI on-board.

    SPIR reported on January 5, 2022, that the company’s Executives presented at CJS Securities 22nd Annual “New Ideas for the New Year” Investor Conference held on January 12, 2022. On December 16, 2021, SPIR reported about its triumphant delivery of Space Force SSC payload to the space outside its 3U LEMUR CubeSat.

    SPIR co-reported with Virgin Orbit on December 9, 2021, about the receipt of relinquishment nod from the Federal Aviation Authority to incorporate the company on Virgin Orbit’s future launch. On December 7, 2021, SPIR reported about receipt of contract under the ESA’s navigation platform known as NAVISP. The company will build current capacities of its constellation and tools development for geolocation signal dispensation.

    On December 2, 2021, SPIR reported about the use of company’s satellite and terrestrial AIS data by the Minehub Technologies Inc. The data will help entitle its commodities program and improve the routing for increased capacity carrier containers.

    On December 1, 2021, SPIR reported that the company’s Executives presented at the following investor conferences.

    • Morgan Stanley 4th Annual Space Summit held on December 7.
    • Virtual Truist Securities 2021 Industrials and Services Summit held on December 7, and
    • Virtual Canaccord Genuity 5th New Space Investor Summit held on December 9, 2021.

    SPIR: Key Financials

    On November 10, 2021, SPIR reported its financial results for the quarter ended September 30, 2021. Some of the key updates are as follows.

    Revenue

    Revenue in the quarter was recorded to be $9.6 million compared to $7.1 million in the same period in 2020.

    Net Loss per Share

    Basic and diluted net loss per share in Q3 2021 was $32.7 million or $0.49 compared to $7.6 million or $0.43 in the same period of 2020.

    Conclusion

    SPIR stock lost its momentum by 76% from the past six months period. The reason for this decline is the recessing economic conditions prevailing globally. The current premarket surge in the stock is due to uncertain reason because the company did not show any recent activity. The analysts are predicting this stock position as groundbreaking for the company’s policies which influence investor turn-out.

  • Here’s the Reason Why Capricor Therapeutics, Inc. (CAPR) Stock is Roaring in the Premarket

    Capricor Therapeutics, Inc. (CAPR) is a biopharmaceutical company engaged in the development of therapeutics for treating an array of diseases. The company’s pipeline product candidate includes CAP-1002 used for treating Duchenne muscular dystrophy and the cytokine storm in COVID-19 patients. The Company is also developing exosomes capable of delivering nucleic acids to treat different diseases.

    The price of CAPR stock during the regular trading on January 24, 2022 was $2.83 with a decline of 2.08%. At last check in the premarket on January 25, 2022, the stock was significantly up by 7.42%.

    CAPR: Events and Happenings

    On January 25, 2022, CAPR reported about its entry into strategic collaboration with Japanese origin Nippon Shinyaku Company. The basic aim of the partnership is the commercialization and distribution of CAP-1002 in the US. On December 13, 2021, CAPR reported its vaccine and developmental portfolio updates mainly focusing on COVID-19. Company’s pre-clinical exosome mRNA vaccine has the capability for a strong T-cell response in a viral infection. In addition, the company will also report topline results from its INSPIRE Phase 2 studies in Q1 2022.

    On November 12, 2021, CAPR reported that the company’s Executives presented at the Virtual TriLink Biotechnologies Annual mRNA Day Conference held on November 16, 2021.

    CAPR: Key Financials

    On November 09, 2021, CAPR announced its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.

    Net Loss per Share

    Basic and diluted net loss per share in Q3 2021 was $3.9 million, or $0.17 compared to $3.9 million, or $0.20 for the same period in 2020.

    Assets

    Total assets in Q3 2021 were recorded to be $43.1 million.

    On September 24, 2021, CAPR reported optimistic final results for its HOPE-2 clinical studies utilizing CAP-1002. On September 22, 2021, CAPR reported that the company’s Executives presented at the conferences namely Virtual Cantor Fitzgerald Global healthcare Conference held on September 30 and Cell & Gene Meeting on the Mesa held on October 13, 2021.

    Conclusion

    CAPR stock is 40% down compared to the last six months period due to the challenges faced by the economy because of the worsening pandemic situation. The current premarket increase in stock price is the consequence of the company’s announcement of its entry into a strategic partnership. The analysts are confident that the current market scenario is favorable for the company’s stock to bloom.